NCT03046316 (LOCAL) is a NA clinical trial of local consolidative treatment in Lung Neoplasms, sponsored by Guangdong Association of Clinical Trials.

Who is sponsoring NCT03046316?

NCT03046316 is sponsored by Guangdong Association of Clinical Trials.

What drugs are being tested in NCT03046316?

Interventions in NCT03046316: local consolidative treatment.

What condition does NCT03046316 study?

NCT03046316 studies Lung Neoplasms.

Is NCT03046316 still recruiting?

NCT03046316 is currently recruiting now. Last updated 23 July 2020.

Last reviewed 2020-07-23 · How we verify

NCT03046316: LOCAL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Local Therapy in Advanced NSCLC With Non-progressive Disease (PD) After First Line Therapy

Recruiting now NA Last updated 23 July 2020

What this trial tests

NA trial testing local consolidative treatment in Lung Neoplasms in 60 participants. Currently enrolling.

Timeline

1 June 2020

Primary endpoint
1 July 2022

1 July 2026

Quick facts

Lead sponsor	Guangdong Association of Clinical Trials
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	1 June 2020
Primary completion	1 July 2022
Estimated completion	1 July 2026
Sites	1 location across China

Drugs / interventions tested

local consolidative treatment

Conditions studied

Lung Neoplasms — all drugs for Lung Neoplasms →

Sponsor

Guangdong Association of Clinical Trials

Who can join

18 and older, any sex, with Lung Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective single arme real-world study clinical study, which aims to investigate the overall benefit and safety of consolidative therapy in advanced NSCLC (stage III/IV) patients , who do not progress after front line systemic therapy (chemotherapy, target therapy or immunological checkpoint inhibitors).

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology.
Bartolomucci A, Nobrega M, Ferrier T, Dickinson K, et al · · 2025 · cited 72× · PMID 40122951 · DOI 10.1038/s41698-025-00876-y
Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
Dong S, Wang Z, Zhang JT, Yan B, et al · · 2024 · cited 54× · PMID 38869865 · DOI 10.1001/jamaoncol.2024.1779
A Review of Circulating Tumor DNA (ctDNA) and the Liquid Biopsy in Cancer Diagnosis, Screening, and Monitoring Treatment Response.
Parums DV. · · 2025 · cited 13× · PMID 40259565 · DOI 10.12659/msm.949300
Circulating tumor DNA (ctDNA)-based minimal residual disease in non-small cell lung cancer.
Tang L, Li R, Wen H, Zhou Q, et al · · 2023 · cited 6× · PMID 39171282 · DOI 10.1016/j.pccm.2023.04.001
Drug development and evidence for lung cancer targeted therapy in Eastern Asia.
Maggie Liu SY, Jin ZY, Deng JY, Zhong SM, et al · · 2024 · cited 2× · PMID 39381018 · DOI 10.1016/j.lanwpc.2024.101090

Verify or expand the search:

Other recruiting trials for Lung Neoplasms

Currently open trials in the same condition.

NCT07476287 — Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult · Phase 2 · recruiting
NCT07509333 — MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients · NA · recruiting
NCT07109154 — DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First- · recruiting
NCT06974604 — Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM · Phase 2 · recruiting
NCT07165691 — TELEhealth Shared Decision-making COaching for Lung Cancer Screening in Primary Care (TELESCOPE) for Hispanics · NA · recruiting

Other Guangdong Association of Clinical Trials trials

Trials by the same sponsor.

NCT07412262 — A Prospective, Single-Arm, Multicenter, Phase II Clinical Study of Chidamide Combined With Ivonescimab in the Treatment · Phase 2 · not yet recruiting
NCT07416058 — PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC · Phase 2 · not yet recruiting
NCT07375316 — A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC · Phase 2 · recruiting
NCT07120698 — Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung) · Phase 2 · recruiting
NCT07198620 — A Real-World Study of IBI351 for KRAS G12C+ NSCLC in China · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03046316 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangdong Association of Clinical Trials
Last refreshed: 23 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03046316.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing